Dextromethorphan and guaifenesin use needs to be monitored very carefully in people with "bad metabolizer" CYP2D6 enzyme amounts and clients that are sedated. This combination medication includes a significant median harmful dose (TD50) to median productive dose (ED50) ratio (or therapeutic index) in these people. Delsym has an entire line https://chemicalglobe.com/